News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prometheus BioScience Inc. Launches ENTOCORT(R) EC (budesonide) Capsules


10/19/2005 5:12:07 PM

SAN DIEGO, Jan. 11 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced that it has begun exclusive marketing, sales and distribution of ENTOCORT(R) EC (budesonide) Capsules in the United States.

"Prometheus is unique in its ability to provide physicians with both pharmaceuticals and clinical diagnostic products that enable physicians to diagnose, stratify, pharmaceutically treat and monitor their patients in order to optimize the patient's therapy," noted Clyde W. Shores, Prometheus' Vice President of Marketing. "ENTOCORT EC is a very important product for physicians and patients, as it is the only FDA-approved product for the majority of Crohn's patients with mild to moderate active disease. The addition of ENTOCORT EC to our portfolio is also an important step in Prometheus' strategy of expanding our commercial franchise with clinically meaningful and proprietary products."

"Prometheus has reduced to practice the concept of 'personalized medicine' to benefit physicians and their patients," stated Michael D. Allen, Prometheus' Vice President of Sales. "We have built strong relationships with gastroenterologists by providing high-value products to aid in the comprehensive treatment of their patients with difficult diseases. We believe that we are well positioned for growth by leveraging our strong commercial presence to exclusively market, sell and distribute ENTOCORT EC in the United States."

ENTOCORT EC Background

AstraZeneca launched ENTOCORT EC Capsules in November 2001. In November 2004, Prometheus entered into an agreement with AstraZeneca LP for the marketing, sales and distribution of ENTOCORT EC beginning in January, 2005.

ENTOCORT EC is a first-line therapy and the only pharmacological product indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, the sites of disease for approximately 70% of patients. ENTOCORT EC is a non-systemic glucocorticosteriod, which means that it works locally or in one area of the body. The most common side effects of ENTOCORT EC observed in clinical trials were headache, respiratory infection, nausea and symptoms of hypercorticism.

Crohn's disease is a chronic inflammatory bowel disease of unknown origin. An estimated 500,000 Americans have the disorder. Flare-ups of the disease can range from mild to severe and involve symptoms such as diarrhea, abdominal pain, fever and sometimes rectal bleeding. The condition can be difficult to manage clinically and consumes a substantial amount of healthcare resources in terms of physician time, procedures and medications.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus' strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating therapeutics and diagnostic services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California. Additional information about Prometheus can be found at http://www.prometheuslabs.com/.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Prometheus cautions that any forward-looking information is not a guarantee of future performance. The Company may not successfully maintain or grow the market for ENTOCORT EC for a variety of reasons. The Company is aware of other products under development and in clinical testing for the treatment of Crohn's disease. To market ENTOCORT EC, the Company is expanding its sales force. The market for personnel is competitive, and there is no assurance that the Company can recruit new personnel on a timely basis. It is difficult to predict the impact of competitive products and pricing.

ENTOCORT is a registered trademark of the AstraZeneca group of companies.

Prometheus Laboratories Inc.

CONTACT: Beth Kriegel, Senior Director, Financial Planning and InvestorRelations of Prometheus Laboratories Inc., +1-858-410-2516


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES